ScholarIQanswers from OpenAlex
MannKind Corporation
FunderResearch funding and supported work
MannKind Corporation is a funder indexed in ScholarIQ from OpenAlex.
What is known about MannKind Corporation?
ScholarIQrecord summary
biopharmaceutical company
How many works does MannKind Corporation have?
ScholarIQindexed works
MannKind Corporation has 484 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for MannKind Corporation?
ScholarIQopenalex
The OpenAlex for MannKind Corporation is on the source record.
What is the ROR of MannKind Corporation?
ScholarIQror
The ROR for MannKind Corporation is on the source record.
What are the most-cited papers on MannKind Corporation?
ScholarIQmost cited works
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William C. Duckworth, Carlos Abraira, Thomas Moritz, Domenic J. Reda, Nicholas Emanuele, Peter D. Reaven, Franklin J. Zieve, Jennifer A. Marks, Stephen N. Davis, Rodney A. Hayward, Stuart Warren, Steven Goldman, Madeline McCarren, Mary Ellen Vitek, William G. Henderson, Grant D. Huang
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
Domenica Rubino, Domenica Rubino, Niclas Abrahamsson, Melanie Davies, Dan Hesse, Frank L. Greenway, Camilla Jensen, Ildiko Lingvay, Ofri Mosenzon, Julio Rosenstock, Miguel A. Rubio, Gottfried Rudofsky, Sayeh Tadayon, Thomas A. Wadden, Dror Dicker, STEP 4 Investigators, M. Friberg, Anders Sjödin, Dror Dicker, Gabriella Segal, Ofri Mosenzon, Muhammad Sabbah, Yael Sofer, Victor Vishlitzky, Eelco W. Meesters, Mirelle Serlie, Arianne van Bon, Helena Cardoso, Paula Freitas, Pedro Carneiro de Melo, Mariana P. Monteiro, Mariana Monteiro, Dírcea Rodrigues, Aysha Badat, P Joshi, Gulam Latiff, Essack A. Mitha, Hans H. Snyman, Elane van Nieuwenhuizen, Olga González Albarrán, Assumpta Caixàs, Carmen de al Cuesta, Pedro Pablo Garcia Luna, Cristobal Morales Portillo, Pedro Mezquita Raya, Miguel Angel Rubio, Niclas Abrahamsson, Johan Hoffstedt, Fredrik von Wowern, Erik Uddman, Birgit Bach-Kliegel, Felix Beuschlein, Stefan Bilz, Alain Golay, Gottfried Rudofsky, Christopher Strey, Н. В. Косей, Т. Ф Татарчук, Тетяна Татарчук, Valentyna Velychko, Olesya Zinych, Stephen Aronoff, Harold E. Bays, Andrew P. Brockmyre, Robert S. Call, Charles Crump, Cyrus V. Desouza, Valerie Espinosa, Almena Free, Winston H. Gandy, Steven A. Geller, Gregory Gottschlich, Frank L. Greenway, Laurie Han-Conrad, Wayne Harper, L A Herman, Mitzie Hewitt, Ph. Hollander, Steven R. Kaster, Anastasios Manessis, Frederick A. Martin, Robert E. McNeill, Alexander V. Murray, Paul Norwood, John C.H. Reed, Julio Rosenstock, Domenica M. Rubino, Domenica M. Rubino, Martin Schear, Mark Warren
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Helen M. Colhoun, Ildiko Lingvay, Paul Brown, John Deanfield, Kirstine Brown‐Frandsen, Steven E. Kahn, Jorge Plutzky, Koichi Node, Alexander Parkhomenko, Lars Rydén, John Wilding, Johannes F.E. Mann, Katherine R. Tuttle, Thomas Idorn, Naveen Rathor, A. Michael Lincoff